Medications

Study: Copanlisib + rituximab slows relapsed indolent lymphoma

Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a study presented during Week 1 of the annual meeting of the American Association ...

Diseases, Conditions, Syndromes

Evidence mounting that COVID-19 can cause diabetes type II

A team of researchers from King's College London and Monash University has created a database of information that relates COVID-19 and type II diabetes. The team has created the database for two reasons—the first is that ...

Medical research

The dark side of antibiotics and what we can do about it

As early as the 13th century, scholars proposed that diseases were caused by 'invisible entities' unseen to the naked eye. However, it was not until the 1670s when Antonie van Leeuwenhoek made his microscope did the theory ...

page 1 from 15